Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $10.00 price target on VYNE Therapeutics (NASDAQ: VYNE) following "solid ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE